H Larsson1, Z Chang1, B M D'Onofrio2, P Lichtenstein1. 1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm,Sweden. 2. Department of Psychological and Brain Sciences,Indiana University,Bloomington, IN,USA.
Abstract
BACKGROUND: No prior twin study has explored the heritability of clinically diagnosed attention deficit hyperactivity disorder (ADHD). Such studies are needed to resolve conflicting results regarding the importance of genetic effects for ADHD in adults. We aimed to estimate the relative contribution of genetic and environmental influences for clinically diagnosed ADHD across the lifespan with a specific focus on ADHD in adults. METHOD: Information on zygosity and sex was obtained from 59514 twins born between 1959 and 2001 included in the nationwide population-based Swedish Twin Registry. Clinical data for ADHD diagnoses (i.e. stimulant or non-stimulant medication for ADHD) were obtained from the Swedish Prescribed Drug Register (PDR) and from the National Patient Register (i.e. ICD-10 diagnosis of ADHD). Twin methods were applied to clinical data of ADHD diagnoses using structural equation modeling with monozygotic (MZ) and dizygotic (DZ) twins. RESULTS: The best-fitting model revealed a high heritability of ADHD [0.88, 95% confidence interval (CI) 0.83-0.92] for the entire sample. However, shared environmental effects were non-significant and of minimal importance. The heritability of ADHD in adults was also substantial (0.72, 95% CI 0.56-0.84). CONCLUSIONS: This study shows that the heritability of clinically diagnosed ADHD is high across the lifespan. Our finding of high heritability for clinically diagnosed ADHD in adults indicates that the previous reports of low heritability are best explained by rater effects, and that gene-identification studies of ADHD in adults need to consider pervasiveness (e.g. multiple raters) and developmentally (e.g. childhood-onset criteria) informative data.
BACKGROUND: No prior twin study has explored the heritability of clinically diagnosed attention deficit hyperactivity disorder (ADHD). Such studies are needed to resolve conflicting results regarding the importance of genetic effects for ADHD in adults. We aimed to estimate the relative contribution of genetic and environmental influences for clinically diagnosed ADHD across the lifespan with a specific focus on ADHD in adults. METHOD: Information on zygosity and sex was obtained from 59514 twins born between 1959 and 2001 included in the nationwide population-based Swedish Twin Registry. Clinical data for ADHD diagnoses (i.e. stimulant or non-stimulant medication for ADHD) were obtained from the Swedish Prescribed Drug Register (PDR) and from the National Patient Register (i.e. ICD-10 diagnosis of ADHD). Twin methods were applied to clinical data of ADHD diagnoses using structural equation modeling with monozygotic (MZ) and dizygotic (DZ) twins. RESULTS: The best-fitting model revealed a high heritability of ADHD [0.88, 95% confidence interval (CI) 0.83-0.92] for the entire sample. However, shared environmental effects were non-significant and of minimal importance. The heritability of ADHD in adults was also substantial (0.72, 95% CI 0.56-0.84). CONCLUSIONS: This study shows that the heritability of clinically diagnosed ADHD is high across the lifespan. Our finding of high heritability for clinically diagnosed ADHD in adults indicates that the previous reports of low heritability are best explained by rater effects, and that gene-identification studies of ADHD in adults need to consider pervasiveness (e.g. multiple raters) and developmentally (e.g. childhood-onset criteria) informative data.
Authors: Stéphanie M van den Berg; Gonneke Willemsen; Eco J C de Geus; Dorret I Boomsma Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2006-01-05 Impact factor: 3.568
Authors: Paul Lichtenstein; Patrick F Sullivan; Sven Cnattingius; Margaret Gatz; Sofie Johansson; Eva Carlström; Camilla Björk; Magnus Svartengren; Alicja Wolk; Lars Klareskog; Ulf de Faire; Martin Schalling; Juni Palmgren; Nancy L Pedersen Journal: Twin Res Hum Genet Date: 2006-12 Impact factor: 1.587
Authors: Björn Wettermark; Niklas Hammar; Carl Michael Fored; C MichaelFored; Andrejs Leimanis; Petra Otterblad Olausson; Ulf Bergman; Ingemar Persson; Anders Sundström; Barbro Westerholm; Måns Rosén Journal: Pharmacoepidemiol Drug Saf Date: 2007-07 Impact factor: 2.890
Authors: Stephen V Faraone; Roy H Perlis; Alysa E Doyle; Jordan W Smoller; Jennifer J Goralnick; Meredith A Holmgren; Pamela Sklar Journal: Biol Psychiatry Date: 2005-01-21 Impact factor: 13.382
Authors: A Merwood; C U Greven; T S Price; F Rijsdijk; J Kuntsi; G McLoughlin; H Larsson; P J Asherson Journal: Psychol Med Date: 2013-01-09 Impact factor: 7.723
Authors: Angela M Reiersen; John N Constantino; Marisa Grimmer; Nicholas G Martin; Richard D Todd Journal: Twin Res Hum Genet Date: 2008-12 Impact factor: 1.587
Authors: Isabell Brikell; Laura Ghirardi; Brian M D'Onofrio; David W Dunn; Catarina Almqvist; Søren Dalsgaard; Ralf Kuja-Halkola; Henrik Larsson Journal: Biol Psychiatry Date: 2017-08-12 Impact factor: 13.382
Authors: Quetzal A Class; Martin E Rickert; Henrik Larsson; Paul Lichtenstein; Brian M D'Onofrio Journal: Br J Psychiatry Date: 2014-09-25 Impact factor: 9.319
Authors: Sharlene Kaye; Josep Antoni Ramos-Quiroga; Geurt van de Glind; Frances R Levin; Stephen V Faraone; Steve Allsop; Louisa Degenhardt; Franz Moggi; Csaba Barta; Maija Konstenius; Johan Franck; Arvid Skutle; Eli-Torild Bu; Maarten W J Koeter; Zsolt Demetrovics; Máté Kapitány-Fövény; Robert A Schoevers; Katelijne van Emmerik-van Oortmerssen; Pieter-Jan Carpentier; Geert Dom; Sofie Verspreet; Cleo L Crunelle; Jesse T Young; Susan Carruthers; Joanne Cassar; Melina Fatséas; Marc Auriacombe; Brian Johnson; Matthew Dunn; Ortal Slobodin; Wim van den Brink Journal: J Atten Disord Date: 2016-02-27 Impact factor: 3.256